Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conferenceseries Ltd: World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Previous Speakers

Yong Yu

Yong Yu

Wellcome Trust Sanger Institute UK

Venkatesan Renugopalakrishnan

Venkatesan Renugopalakrishnan

1Boston Children’s Hospital, USA 2Harvard Medical School, USA 3Northeastern University USA

Michael L. Nickerson

Michael L. Nickerson

National Institutes of Health Bethesda USA

Vadim R Viviani

Vadim R Viviani

Universidade Federal de Sao Carlos Brazil

Carlos R. Prudencio

Carlos R. Prudencio

Adolfo Lutz Institute Brazil

Peter L. Nagy

Peter L. Nagy

Columbia University USA

Juliana Ferreira de Santana

Juliana Ferreira de Santana

Universidade Federal do Parana Brazil

Wai Kit Chan

Wai Kit Chan

Middlesex University School of Science & Technology UK

Cell Therapy 2018

About Conference

After successful completion of last six International conferences, ConferenceSeries Ltd welcome you all to attend 7th International Conference and Exhibition on Cell & Gene Therapy (CELL THERAPY 2018) follows the theme “Exploring the novel research and innovations in Cell & gene therapy” which will be held during March 15-17, 2018, London, UK. We cordially invite all the participants who are interested in sharing their knowledge and research in the arena of Cell & Gene Therapy conference.

Cell and Gene Therapy Conference is to ameliorate the knowledge, awareness, and education on cell and gene therapy leading to the discovery of genetic and cellular therapies which aid to alleviate the human disease as it is the most significant emerging technology in the eyes of Medical, Biotechnology, Pharmaceuticals and Academia. Cell and Gene Therapy Conference 2018 is an excellent opportunity for the delegates from Universities and Institutes to interact with the world class Scientists. 

Cell Therapy Conferences will provide a perfect platform to all the Doctors, Researchers Business Delegates and Scientists to approach and deliver all the attendees about the latest scientific advancements on the respective sphere. Gene Therapy Conferences strategic astuteness is to be an event for bringing together Scientists, Physicians, International mix of leading Universities, Cell Gene Therapy Institutions to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.

This three-day Gene Therapy Event will address key issues concerning cell and gene therapy in the broader context of cellular and genetic disorder. Organized around daily themes, the Conference focuses on moving from present knowledge to future solutions.

Global markets for stem cells by BCC Research (2012), cited by Ministry of Food and Drug Safety, predicted the global market size of stem cell therapy product would be 6.6 billion dollars in 2016 and grow 11.7% on average every year. Currently, Europe cell therapy and gene therapy occupy share market of 872 million dollars. Europe's is 10.9% (1.5 billion dollars in 2016).

The forum of Scientists, students, research scholars and other professionals from all corners of the globe, come together to discuss future science. Each session of the meeting will be included with expert lectures, poster and discussions, join us to design sustainable processes, innovations by which and how these strategies drive new policies, advances the business and human health protection. We are glad to invite you on behalf of organizing committee to join us, where you are the decision maker for future at Cell and gene therapy 2018 congress.

ConferenceSeries Ltd Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.

The previous conferences on Cell & Gene Therapy which were held at Madrid, Spain and  London, UK have explained Research & Advancements in Cell and Gene Therapy, gained so much of interest for eminent scientists all over the world in the field of Cell & Gene Therapy. Now it is the time for the 7th International Conference and Exhibition on Cell & Gene Therapy to address Exploring the novel research and innovations in Cell and Gene therapy  which will be held on March 15-17, 2017 at London, UK.

For More details about the Conference & Interest towards participation, Kindly contact Program Manager
Cell and Gene Therapy 2018
Hurry Up limited slots available!!

Target Audience

Cell and Gene Therapy Students, Scientists

Cell and Gene Therapy Researchers

Cell and Gene Therapy Faculty

Cell and Gene Therapy Associations and Societies

Cell and Gene Therapy physicians

Cell and Gene Therapy advanced practice registered nurses,

Allied health professionals in the fields of Cell and Gene Therapy,hematology, oncology, neurology, family medicine and internal medicine.

Stem Cell Students, Scientists

Stem Cell Researchers

Stem Cell Faculty

Stem Cell Associations and Societies

Business Entrepreneurs

Training Institutes

Software developing companies

 

Sessions/Tracks

Track-1 Stem Cell Therapies:

Cell therapy is defined as the therapy in which cellular material is injected into a patient in order to recover the healthy tissue. Cell therapy is targeted at many clinical indications in multiple organs by means of several modes of cell delivery. Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Stem cells are a class of undifferentiated cells which are able to differentiate into required or specialized cell types. Adult or somatic stem cells exist throughout the body after embryonic development and are found available inside the different types of tissue. The stem cell methodology includes the phases of Stem cell or progenitor cell engraftment, differentiation followed by long term replacement of damaged tissue.

Related Cell Therapy Conferences | Gene Therapy Conferences:

2nd World Congress on Human Genetics Edinburgh, Scotland, September 14-15,2017; 3rd International Conference on Systems and Synthetic Biology July 20-21,2017 at Munich, Germany; 10th International Conference on Genomics and Pharmacogenomics Madrid, Spain, March 21-23, 2018; 9th Annual Conference on Stem Cell and Regenerative Medicine, Berlin, Germany, Sep 25-26, 2017;7th International Conference on Tissue Engineering & Regenerative Medicine October 02-04, 2017 Barcelona, Spain; 17th Euro Biotechnology Congress September 25-27, 2017 Berlin, Germany

Track-2 Cell Line Development:

A stem-cell line is a group of undifferentiated stem cells which is cultured invitro and can be propagated indefinitely. While stem cells can propagate indefinitely in culture due to their inherent cellular properties, immortalized cells would not normally divide indefinitely but have gained this ability to sustain due to mutation. The Immortalized cell lines can be generated from cells by means of isolating cells from tumors or induce mutations to make the cells immortal. An immortalised cell line is a population of multicellular organism cells which has not proliferates indefinitely. Due to mutation, the cells evaded normal cellular senescence and instead undergoing continuous cell division. A key factor in reducing the production costs of biopharmaceuticals is the development of cell lines which in turn produce a high yield of product.

Related Cell Therapy Conferences | Gene Therapy Conferences:

2nd World Congress on Human Genetics Edinburgh, Scotland, September 14-15,2017; 3rd International Conference on Systems and Synthetic Biology July 20-21,2017 at Munich, Germany; 10th International Conference on Genomics and Pharmacogenomics Madrid, Spain, March 21-23, 2018; 9th Annual Conference on Stem Cell and Regenerative Medicine, Berlin, Germany, Sep 25-26, 2017;7th International Conference on Tissue Engineering & Regenerative Medicine October 02-04, 2017 Barcelona, Spain; 17th Euro Biotechnology Congress September 25-27, 2017 Berlin, Germany

Track-3 Vectors for Gene Therapy:

Classical methods of gene therapy include transfection. It became inefficient and limited mainly due to delivery of gene into actively proliferating cells invitro. Gene therapy utilizes the delivery of DNA into cells by means of vectors such as biological nanoparticles or viral vectors and non-viral methods. The Several kinds of viruses vectors used in gene therapy are retrovirus, adenovirus, adeno-associated virus and herpes simplex virus. While other recombinant viral vector systems have been developed, retroviral vectors remain the most popular vector system for gene therapy protocols and widest application due to their historical significance as the first vectors developed for efficient gene therapy application and the infancy of the field of gene therapy

Related Cell Therapy Conferences | Gene Therapy Conferences:

2nd World Congress on Human Genetics Edinburgh, Scotland, September 14-15,2017; 3rd International Conference on Systems and Synthetic Biology July 20-21,2017 at Munich, Germany; 10th International Conference on Genomics and Pharmacogenomics Madrid, Spain, March 21-23, 2018; 9th Annual Conference on Stem Cell and Regenerative Medicine, Berlin, Germany, Sep 25-26, 2017;7th International Conference on Tissue Engineering & Regenerative Medicine October 02-04, 2017 Barcelona, Spain; 17th Euro Biotechnology Congress September 25-27, 2017 Berlin, Germany

Track-4 Gene and Cell Therapy for Rare and Common Diseases:

Gene therapy is used to treat inherited Muscular disorder, cardiovascular disorder, HIV, cancer etc. In stem cell transplants, stem cells replace cells damaged by chemotherapy or disease or as a way for the donor's immune system to provoke immunity against some types of cancer and blood-related diseases, such as leukemia. Cellular Therapy is internationally recognized for its novel approaches in treating blood related disorders like leukemia, lymphoma, myeloma, and other life threatening diseases. The stem cell transplantation of hematopoietic stem cells (HSCT) in which the allogeneic hematopoietic stem cells are harvested from healthy donors of same species and autologous stem cell from the patient itself. Both therapies use high dosage cytotoxic medication in order to induce higher remission rates against malignant diseases. Autologous HSCT preferably used in relapsed malignant high-grade lymphoma and Allogeneic HSCT preferred for therapeutic effect against acute leukemia with unfavorable prognosis in a high percentage of patients. The Recent developments based on the expansion of the donor pool for allogeneic stem cells in order to reduce dosage as well as chemotherapeutic toxicity of allogeneic transplantation with sustainable anti-leukemia efficacy.

 Related Cell Therapy Conferences | Gene Therapy Conferences:

2nd World Congress on Human Genetics Edinburgh, Scotland, September 14-15,2017; 3rd International Conference on Systems and Synthetic Biology July 20-21,2017 at Munich, Germany; 10th International Conference on Genomics and Pharmacogenomics Madrid, Spain, March 21-23, 2018; 9th Annual Conference on Stem Cell and Regenerative Medicine, Berlin, Germany, Sep 25-26, 2017;7th International Conference on Tissue Engineering & Regenerative Medicine October 02-04, 2017 Barcelona, Spain; 17th Euro Biotechnology Congress September 25-27, 2017 Berlin, Germany

Track-5 Tissue Science & Regenerative Medicine:

Regenerative medicine is the branch of translational research deals with the process of replacing, engineering or regenerating human cells, tissues or organs in order to restore or establish normal functionality of cell. Regenerative medicine is the combination of   tissue engineering and molecular biology .Cell therapy mediate cell repair via five primary mechanisms:  providing an anti-inflammatory effect, homing to damaged tissues and recruiting other cells, such as endothelial progenitor cells for necessary tissue growth, supporting tissue remodeling over scar formation, inhibiting apoptosis programmable cell death, and differentiating tissues into bone, cartilage, tendon, and ligament tissue.

 Related Cell Therapy Conferences | Gene Therapy Conferences:

2nd World Congress on Human Genetics Edinburgh, Scotland, September 14-15,2017; 3rd International Conference on Systems and Synthetic Biology July 20-21,2017 at Munich, Germany; 10th International Conference on Genomics and Pharmacogenomics Madrid, Spain, March 21-23, 2018; 9th Annual Conference on Stem Cell and Regenerative Medicine, Berlin, Germany, Sep 25-26, 2017;7th International Conference on Tissue Engineering & Regenerative Medicine October 02-04, 2017 Barcelona, Spain; 17th Euro Biotechnology Congress September 25-27, 2017 Berlin, Germany

Track-6 Molecular Basis of Epigenetics

Epigenetics refers to changes in a chromosome which has influence on gene activity and expression. It is also used to describe any heritable phenotypic change that doesn't derive from a modification of the genome, such as prions. Epigenetics is the mechanism for storing and perpetuating or continuing indefinitely a “memory” at the cellular level. The basic molecular epigenetic mechanisms that are widely studied at present – regulation of chromatin structure of cell through histone post-translational modifications and covalent modification of DNA principally through the method of DNA methylation. Chromatin is a dynamic structure that integrates potentially hundreds of signals from the cell surface and has effects of coordinated and appropriate transcriptional response in cell. It is increasingly clear that epigenetic marking of chromatin and DNA itself is an important component of the signal integration of entire function that is performed by the genome. Moreover, the changes in the epigenetic state of chromatin in cell can have lasting effects on behavioral changes.

Related Cell Therapy Conferences | Gene Therapy Conferences:

2nd World Congress on Human Genetics Edinburgh, Scotland, September 14-15,2017; 3rd International Conference on Systems and Synthetic Biology July 20-21,2017 at Munich, Germany; 10th International Conference on Genomics and Pharmacogenomics Madrid, Spain, March 21-23, 2018; 9th Annual Conference on Stem Cell and Regenerative Medicine, Berlin, Germany, Sep 25-26, 2017;7th International Conference on Tissue Engineering & Regenerative Medicine October 02-04, 2017 Barcelona, Spain; 17th Euro Biotechnology Congress September 25-27, 2017 Berlin, Germany

Track-7 Clinical Trials on Cell and Gene Therapy

Clinical trials of CGT products often varying from the clinical trials design for other types of pharmaceutical products .This differences in trial design are necessitated by the distinctive features of these products. The clinical trials also reflect previous clinical experience and evidence of medicine. Early experiences with CGT products indicate that some CGT products may pose substantial risks to subjects due to effect at cellular and genetic level. The design of early-phase clinical trials of Cell and Gene Therapy products often involves the following consideration of clinical safety issues, preclinical issues, and chemistry, manufacturing and controls (CMC) issues that are encountered.

 Related Cell Therapy Conferences | Gene Therapy Conferences:

2nd World Congress on Human Genetics Edinburgh, Scotland, September 14-15,2017; 3rd International Conference on Systems and Synthetic Biology July 20-21,2017 at Munich, Germany; 10th International Conference on Genomics and Pharmacogenomics Madrid, Spain, March 21-23, 2018; 9th Annual Conference on Stem Cell and Regenerative Medicine, Berlin, Germany, Sep 25-26, 2017;7th International Conference on Tissue Engineering & Regenerative Medicine October 02-04, 2017 Barcelona, Spain; 17th Euro Biotechnology Congress September 25-27, 2017 Berlin, Germany

Track-8 Plant Cell Rejuvenation:

The extract derived from the plant cell culture technology is being harnessed and utilized as an active ingredient in anti-aging skincare products. In recent years, researchers have identified naturally occurring botanicals with substantial antioxidant activity proven to protect skin stem cells from UV-induced oxidative stress, inhibit inflammation, neutralize free radicals and reverse the effects of photoaging by means of anti-oxidant activity. Consequently, cosmeceutical products containing plant stem cell derived extracts have the ability to promote healthy cell proliferation and protect against UV-induced dermatological cellular damage in humans. In contrast to epidermal stem cells, plant stem cells are totipotent that they are capable of regenerating an entirely new, whole plant. Through innovative plant stem cell technology, scientists are able to extract tissue from botanicals and regenerate stem cells can be harnessed for use in humans. The use of stem cells derived from botanicals plant, rather than human stem cells, avoids the controversy surrounding the source or methods of extraction of human stem cells while still harnessing the potential of these intriguing cells and its effect in anti photoaging.

 Related Cell Therapy Conferences | Gene Therapy Conferences:

2nd World Congress on Human Genetics Edinburgh, Scotland, September 14-15,2017; 3rd International Conference on Systems and Synthetic Biology July 20-21,2017 at Munich, Germany; 10th International Conference on Genomics and Pharmacogenomics Madrid, Spain, March 21-23, 2018; 9th Annual Conference on Stem Cell and Regenerative Medicine, Berlin, Germany, Sep 25-26, 2017;7th International Conference on Tissue Engineering & Regenerative Medicine October 02-04, 2017 Barcelona, Spain; 17th Euro Biotechnology Congress September 25-27, 2017 Berlin, Germany

Track-9 Bioengineering Therapeutics:

Tissue engineering or bioengineering is the combinational usage of cells, engineering, materials methods, suitable biochemical and physicochemical factors in order to improve or replace the infected biological tissues. The field includes the development  of  materials, devices,  techniques to detect and  differentiate disease states ,the treatment response, aid tissue healing, precisely deliver treatments to tissues or cells, signal early changes in health status, and provide implantable bio artificial replacement organs for recover or establish of healthy tissue .Techniques developed here identify and detect biomarkers of disease sub-types, progression, and treatment response, from tissue imaging to genetic testing and individual cell analysis, that aid the more rapid development of new treatments and guide their clinical applications in treating the disorder. It includes the usage of computational modeling, bioinformatics, and quantitative pharmacology to integrate data from diverse experimental and clinical sources to discover new drugs and specific drug targets, as well as to design more efficient and informative preclinical, clinical safety and efficacy studies.

Related Cell Therapy Conferences | Gene Therapy Conferences:

2nd World Congress on Human Genetics Edinburgh, Scotland, September 14-15,2017; 3rd International Conference on Systems and Synthetic Biology July 20-21,2017 at Munich, Germany; 10th International Conference on Genomics and Pharmacogenomics Madrid, Spain, March 21-23, 2018; 9th Annual Conference on Stem Cell and Regenerative Medicine, Berlin, Germany, Sep 25-26, 2017;7th International Conference on Tissue Engineering & Regenerative Medicine October 02-04, 2017 Barcelona, Spain; 17th Euro Biotechnology Congress September 25-27, 2017 Berlin, Germany

Track-10 Nano Therapy

Diseases can be treated using viruses as vector to deliver genes in gene therapy. Viruses as gene vector, however, can themselves cause problems in that they may initiate inflammation and the genes may be expressed at too high a level or for too long period of exposure. The goal of Nano technology in gene therapy is delivery of therapeutic genes without a virus, using nanoparticles as non-viral vector to deliver the genes.  The particles can be made with multiple layers so the outer layer with covering of peptide that can target the particles to cells of interest at specific site. The emergent Nanotechnology in gene therapy is used to develop unique approaches in treating the retinopathies and the development of micro and nano dimensional artificial antigen presenting cells (aAPCs) for cancer immunotherapy. These aAPCs mimic the natural signals in immunity that killer T-cells receive when there is an invader (bacteria, virus, cancer cell, etc.) in the body.

Related Cell Therapy Conferences | Gene Therapy Conferences:

2nd World Congress on Human Genetics Edinburgh, Scotland, September 14-15,2017; 3rd International Conference on Systems and Synthetic Biology July 20-21,2017 at Munich, Germany; 10th International Conference on Genomics and Pharmacogenomics Madrid, Spain, March 21-23, 2018; 9th Annual Conference on Stem Cell and Regenerative Medicine, Berlin, Germany, Sep 25-26, 2017;7th International Conference on Tissue Engineering & Regenerative Medicine October 02-04, 2017 Barcelona, Spain; 17th Euro Biotechnology Congress September 25-27, 2017 Berlin, Germany

Track-11 Gene Editing Technology:

Genome editing with engineered nucleases (GEEN) is emergent type of genetic engineering. GEEN is the technology in which DNA is inserted, deleted or replaced in the genome. The emergence of highly versatile genome-editing technologies has provided investigators with the ability to rapidly and economically introduce sequence-specific modifications into the genomes of a broad spectrum of cell types and organisms. It also promotes various changes in sub cellular level. Genome editing itself also holds tremendous potential for treating the underlying various idiopathic genetic causes of certain diseases. The core technologies now most commonly used  techniques to facilitate genome editing are clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9),  transcription activator-like effector nucleases (TALENs), zinc-finger nucleases (ZFNs), and homing endonucleases or meganucleases.

 Related Cell Therapy Conferences | Gene Therapy Conferences:

2nd World Congress on Human Genetics Edinburgh, Scotland, September 14-15,2017; 3rd International Conference on Systems and Synthetic Biology July 20-21,2017 at Munich, Germany; 10th International Conference on Genomics and Pharmacogenomics Madrid, Spain, March 21-23, 2018; 9th Annual Conference on Stem Cell and Regenerative Medicine, Berlin, Germany, Sep 25-26, 2017;7th International Conference on Tissue Engineering & Regenerative Medicine October 02-04, 2017 Barcelona, Spain; 17th Euro Biotechnology Congress September 25-27, 2017 Berlin, Germany

Track-12 Advanced Gene Therapeutics:

Functionality of biomaterials for these forms is depends upon the chemical reaction such as localized or systemic response at the surface tethered moieties or encapsulated therapeutic factors such as drugs, genes, cells, growth factors, hormones and other active agents to specific target sites. The application of functional biomaterials is rehabilitation, reconstruction, regeneration, repair, ophthalmic applications and act as therapeutic solutions. It has the property of biocompatibility and produce inertness response to the tissue.   The biomaterial-mediated gene therapy aim to use polymeric gene therapy systems to halt the progression of neuron loss through neuroprotective routes and it combine stem cell therapy and biomaterial delivery system in order to enhance regeneration or repair after ischemic injury.

 Related Cell Therapy Conferences | Gene Therapy Conferences:

2nd World Congress on Human Genetics Edinburgh, Scotland, September 14-15,2017; 3rd International Conference on Systems and Synthetic Biology July 20-21,2017 at Munich, Germany; 10th International Conference on Genomics and Pharmacogenomics Madrid, Spain, March 21-23, 2018; 9th Annual Conference on Stem Cell and Regenerative Medicine, Berlin, Germany, Sep 25-26, 2017;7th International Conference on Tissue Engineering & Regenerative Medicine October 02-04, 2017 Barcelona, Spain; 17th Euro Biotechnology Congress September 25-27, 2017 Berlin, Germany

Track-13 Genetic and Genome Medicine:

Genetics in Health and Disease in which therapy utilizes genetics, imaging and biological indicators to understand predisposition to disease, what constitutes health during childhood and throughout the life course. Gene and Protein Function are used to develop tools, skills and resources to elucidate gene function and to inform development of new therapies using state-of the-art technologies. Personalised Medicine and Patient benefit is considered to ensure basic science discoveries of disease mechanisms and patients genomes are used to produce best effect to improve patients’ lives which include better diagnostics, identification of biomarkers and targeting of therapies.

 Related Cell Therapy Conferences | Gene Therapy Conferences:

2nd World Congress on Human Genetics Edinburgh, Scotland, September 14-15,2017; 3rd International Conference on Systems and Synthetic Biology July 20-21,2017 at Munich, Germany; 10th International Conference on Genomics and Pharmacogenomics Madrid, Spain, March 21-23, 2018; 9th Annual Conference on Stem Cell and Regenerative Medicine, Berlin, Germany, Sep 25-26, 2017;7th International Conference on Tissue Engineering & Regenerative Medicine October 02-04, 2017 Barcelona, Spain; 17th Euro Biotechnology Congress September 25-27, 2017 Berlin, Germany

Track-14 Gene Therapy Commercialization:

The global market for cell and gene based therapies is expected to surpass the $20 billion USD mark by 2025, with an annual growth rate of 21%. The main targets for cell – based therapies are high impact disease areas with significant incurable needs, including cancer, heart disease, neurodegenerative diseases, musculoskeletal disorders and autoimmune diseases. Gene therapies should then not be rushed to market but companies should gather the required data about the impact of therapy in human community with the appropriate duration of follow-up to allow proper evaluation by payers. In addition, it is key to think about potential reimbursement of the techniques and also the pricing strategies, including risk sharing, as soon as the early clinical development phase

Related Cell Therapy Conferences | Gene Therapy Conferences:

2nd World Congress on Human Genetics Edinburgh, Scotland, September 14-15,2017; 3rd International Conference on Systems and Synthetic Biology July 20-21,2017 at Munich, Germany; 10th International Conference on Genomics and Pharmacogenomics Madrid, Spain, March 21-23, 2018; 9th Annual Conference on Stem Cell and Regenerative Medicine, Berlin, Germany, Sep 25-26, 2017;7th International Conference on Tissue Engineering & Regenerative Medicine October 02-04, 2017 Barcelona, Spain; 17th Euro Biotechnology Congress September 25-27, 2017 Berlin, Germany

Track-15  Markets & Future Prospects for Cell & Gene Therapy:

The enormous number of companies involved in cell therapy has increased progression remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 305 of these are profiled 291 alliances. Of these companies, 170 are involved in stem cells. The Profiles of 72 academic institutions in the US involved in cell therapy along with their commercial collaborations. Allogenic technology with more than 350 clinical trials is poised to dominate the commercialization of cell therapies in market. Further R&D in cell and gene therapy is expected to bloom given the biologically based advantages.

Related Cell Therapy Conferences | Gene Therapy Conferences:

2nd World Congress on Human Genetics Edinburgh, Scotland, September 14-15,2017; 3rd International Conference on Systems and Synthetic Biology July 20-21,2017 at Munich, Germany; 10th International Conference on Genomics and Pharmacogenomics Madrid, Spain, March 21-23, 2018; 9th Annual Conference on Stem Cell and Regenerative Medicine, Berlin, Germany, Sep 25-26, 2017;7th International Conference on Tissue Engineering & Regenerative Medicine October 02-04, 2017 Barcelona, Spain; 17th Euro Biotechnology Congress September 25-27, 2017 Berlin, Germany

Market Analysis

Importance & Scope:

Scope: The Scope of the conference is to gather all the Doctors, Researchers, Business Delegates and Scientists to approach and deliver all the attendees about the latest scientific advancements on the respective sphere. This Cell and Gene Therapy Conference is the premier event focusing on understanding individual and organizational behaviour and decision-making related to genetics and molecular biology, biotechnology, pharmaceuticals, medicals and academia.

Importance: Conference on Cell & Gene Therapy is a much celebrated conference which basically deals with the latest research and developments in the sphere of Cell and molecular biology. This Conference will provide a perfect platform to all the International mix of leading Research Scholars, and Scientists achieved eminence in their field of study, research academicians from the universities and research institutions, industrial research professionals and business associates along with Ph.D. Students to come and inform all the attendees about the latest scientific advancements on the respective sphere.

 

Top Major Societies Associated with Cell and Gene Therapy

  • British Society and Gene and Cell Therapy
  • American Society of Gene and Cell Therapy (ASGCT)
  • Australasian Gene Therapy Society (AGTS)
  • Austrian Network for Gene Therapy
  • British Society of Gene Therapy (BSGT)
  • European Society of Gene and Cell Therapy (ESGCT)
  • Finnish Gene Therapy Society (FGTS)
  • German Gene Therapy Society (DGGT)
  • International Society for Cancer Gene Therapy (ISCGT)
  • Irish Society for Gene & Cell Therapy (ISGCT)
  • Israeli Society of Gene & Cell Therapy (ISGCT)
  • Japan Society of Gene Therapy (JSGT)
  • Korean Society of Gene and Cell Therapy (KSGCT)
  • Netherlands Society of Gene and Cell Therapy (NVGCT)
  • Société Francophone de ThérapieCellulaire et  Génique (SFTCG)
  • Spanish Society of Gene and Cell Therapy (SETGyC)
  • Swedish Society for Gene and Cell Therapy (SSGCT)
  • Turkish Society of Gene & Cell Therapy (TSGCT)

Figure: Industries Associated with Cellular Therapies

 

Top Research Institutes of Cell and Gene Therapy Globally

Figure: List of Research Institutes

Market Value on Cell and Gene Therapy:

The global stem cell therapy market is expected to reach $330 million by 2020, at a CAGR of 39.5% from 2015 to 2020

The global stem cell market in 2015is expected to be dominated by North America, followed by Asia-Pacific and Europe. However, Asia-Pacific market is expected to surpass North America by 2020, owing to the high number of ongoing research activities.

Autologous Stem Cell and Non-Stem Cell Based Therapies market is currently estimated as $650 million, including products of all application areas. This market is anticipated to reach $2.2 billion by 2017, growing at a CAGR of 21%. ACT has already been successful in the treatment of prostate cancer, skin burns, cosmetic surgeries, skin substitutes, wound healing, pressure ulcers, etc.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market, Revenue Forecast

Figure: Market Value

The markets for gene therapy are difficult to estimate as there is only one approved gene therapy product and it is marketed in China since 2004. Gene therapy markets are estimated for the years 2014-2024. The estimates are based on epidemiology of diseases to be treated with gene therapy, the portion of those who will be eligible for these treatments, competing technologies and the technical developments anticipated in the next decades.

Products manufactured by the industry related cell therapy and its market Value:

Global markets for stem cells by BCC Research (2012), cited by Ministry of Food and Drug Safety, predicted the global market size of stem cell therapy product would be 6.6 billion dollars in 2016 and grow 11.7% on average every year. Currently, US's stem cell therapy product occupying the biggest market share amounts to 1.3 billion dollars and Europe's is 872 million dollars. US's stem cell therapy product market is predicted to have an average annual growth rate of 11.5% (2.3 billion dollars in 2016), and Europe's is 10.9% (1.5 billion dollars in 2016). Until August 1, 2013, three stem cell therapies has acquired a sale permit for domestic use in Korea: Hearticellgram-AMI by FCB-Phamicell (the world's first stem cell therapy product), Cartistem by Medipost (the world's first allogenous stem cell therapy product) and Cupistem by Anterogen. Besides, 24 medicines are undergoing clinical trial till January 1, 2013.

Global markets for stem cells therapy product

Figure: Fund Allotment to Cell and Gene Therapy

US$3 billion state taxpayer-funded institute for stem cell research, the California Institute for Regenerative Medicine. It hopes to provide $300 million a year. However, in June 6, 2006, there were delays in the implementation of the California program and it is believed that the delays will continue for the significant future.  On July 21, 2006, Governor Arnold Schwarzenegger (R-Calif.) authorized $150 million in loans to the Institute in an attempt to jump start the process of funding research.

Semma Therapeutics, a company developing a cell therapy for Type 1 diabetes, announced today that it has closed a $44 million Series A consisting of equity financing and strategic funding. The Series A financing is led by MPM Capital, with Fidelity Biosciences, ARCH Venture Partners, and Medtronic participating. Alongside the equity financing, Semma entered into an undisclosed agreement with Novartis Pharmaceuticals.

NIH provided US$ 258 Million in funding for three SF universities, and US$ 41 Million to SF start up firms through Small Business Innovation Research grant scheme.

Past Conference Report

Cell Therapy 2017

6th International Conference and Exhibition on Cell and Gene Therapy, was organized during Mar 27-28, 2017 at Madrid, Spain. The conference was marked with the attendance of Editorial Board Members of supporting journals, Scientists, young and brilliant researchers, business delegates and talented student communities representing more than 25 countries, who made this conference fruitful and productive.

This conference was based on the theme “Exploring the novel research and innovations in Cell & gene therapy Cell Therapy 2017” which included the following scientific tracks:  

Cell Therapy
Cellular Therapy Technologies
Cell Therapy of Cardiovascular Disorders
Cell Therapy for Cancer
Cell Culture & Bioprocessing:
Cell Science & Stem Cell Research:
Cell Line Development
Tissue Science & Regenerative Medicine
Gene Therapy
Viral gene therapy
Diabetis Gene Therapy
Vectors for Gene Therapy
Molecular Epigenetics
Genetics & Genomic Medicine
Gene Therapy Commercialization
Clinical trials in cell and gene therapy
Gene Therapy for rare & Common Diseases
Gene Editing Technology
Cell Therapy for Neurological Disorders
Ethical Issues in Cell & Gene Therapy
Regulatory & Safety Aspects of Cell & Gene Therapy
Clinical Trails on Cell & Gen Therapy
Markets & Future Prospects for Cell & Gene Therapy

Cell & Gene Therapy Products The Organizing Committee would like to thank the moderator Dr. José Sánchez del Río (Carlos III Madrid University, Spain) for her contribution which resulted in smooth functioning of the conference.

The conference proceeded through various scientific sessions and plenary lectures, of which the following topics were highlighted as Keynote presentations:

Falk  Heinrichsohn- Cellular therapy, an autologous cellular PoC approach to satisfy patient´s needs (Aristoloft Lda,Portugal)
 

Ricardo Baptista - Development of cost efficient platforms for the industrial manufacturing of pluripotent stem cell-derived products for cell therapy: Cell expansion is the starting point (Cell and Gene Therapy Catapult, UK)

Victor Nurcombe - Affinity-selection of heparan sulfate glycosaminoglycans: A promising strategy to augment stem cell therapy (IMB A*STAR Singapore)

 

Various sessions were chaired and co-chaired by: Falk  Heinrichsohn - Aristoloft Lda,Portugal; Tushar Patel  - Mayo Clinic , USA;

Hans Sollinger -  University of Wisconsin School of Medicine and Public Health, USA; María Jesús del Olmo Barros- Autonomous University from Madrid, Spain

ConferenceSeries LLC has taken the privilege of felicitating Cell Therapy 2017 Organizing Committee, Editorial Board Members and Keynote Speakers who supported for the success of this conference.

The esteemed guests, keynote speakers and researchers shared their innovative research and vast experience through their informative presentations at the podium of Cell Therapy 2017. We are glad to inform that all accepted abstracts for the conference have been published in Journal of Stem Cell Research & Therapy: Open Access as a special issue.

We are also obliged to various experts, company representatives and other eminent scientists who supported the conference by facilitating the discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance. With the unique feedback from the conference, ConferenceSeries LLC would like to proudly announce the commencement of the " 7th  International Conference and Exhibition on Cell and Gene Therapy " to be organized during Mar 15-17, 2018 at Berlin, Germany.

 Mark your calendars for the upcoming Conference; we are hoping to see you soon!

 

 


Past Reports  Gallery  

Supported By

Journal of Stem Cell Research & Therapy Journal of Genetic Syndromes & Gene Therapy Journal of Cell Science & Therapy

All accepted abstracts will be published in respective Conferenceseries International Journals.

Abstracts will be provided with Digital Object Identifier by


Media partners & Collaborators & Sponsors

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner